Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 305

  • Showing results for a modified search because your search retrieved no results.
1.

Mutations associated with virological response to darunavir/ritonavir in HIV-1-infected protease inhibitor-experienced patients.

Descamps D, Lambert-Niclot S, Marcelin AG, Peytavin G, Roquebert B, Katlama C, Yeni P, Felices M, Calvez V, Brun-Vézinet F.

J Antimicrob Chemother. 2009 Mar;63(3):585-92. doi: 10.1093/jac/dkn544. Epub 2009 Jan 15.

PMID:
19147519
2.

Clinically validated mutation scores for HIV-1 resistance to fosamprenavir/ritonavir.

Masquelier B, Assoumou KL, Descamps D, Bocket L, Cottalorda J, Ruffault A, Marcelin AG, Morand-Joubert L, Tamalet C, Charpentier C, Peytavin G, Antoun Z, Brun-Vézinet F, Costagliola D; ANRS Resistance Study Group.

J Antimicrob Chemother. 2008 Jun;61(6):1362-8. doi: 10.1093/jac/dkn127. Epub 2008 Apr 4.

PMID:
18390885
3.

Virological response to darunavir in patients infected with HIV is linked to darunavir resistance-associated mutations corrected by the count of mutations with positive impact and is not associated with pharmacological and combined virological/pharmacological parameters.

Dailly E, Rodallec A, Allavena C, Deslandes G, Garnier E, Billaud E, Ferré V, Reliquet V, Bouquié R, Raffi F, Jolliet P.

Fundam Clin Pharmacol. 2012 Aug;26(4):538-42. doi: 10.1111/j.1472-8206.2011.00949.x. Epub 2011 May 5.

PMID:
21545648
4.

Virological response to darunavir/ritonavir-based regimens in antiretroviral-experienced patients (PREDIZISTA study).

Pellegrin I, Wittkop L, Joubert LM, Neau D, Bollens D, Bonarek M, Girard PM, Fleury H, Winters B, Saux MC, Pellegrin JL, Thiébaut R, Breilh D; ANRS Co3 Aquitaine Cohort.

Antivir Ther. 2008;13(2):271-9.

PMID:
18505178
5.

Genotypic resistance analysis of the virological response to fosamprenavir-ritonavir in protease inhibitor-experienced patients in CONTEXT and TRIAD clinical trials.

Marcelin AG, Flandre P, Molina JM, Katlama C, Yeni P, Raffi F, Antoun Z, Ait-Khaled M, Calvez V.

Antimicrob Agents Chemother. 2008 Dec;52(12):4251-7. doi: 10.1128/AAC.00514-08. Epub 2008 Oct 13.

6.

Interpretation of genotypic HIV-1 resistance to darunavir and virological response: validation of available systems and of a new score.

De Luca A, Di Giambenedetto S, Maserati R, Gianotti N, Narciso P, Antinori A, Di Perri G, Prosperi MC, Baldanti F, Micheli V, Zazzi M, Perno CF, Santoro MM; TMC114-C226 study group; ARCA study group.

Antivir Ther. 2011;16(4):489-97. doi: 10.3851/IMP1799.

PMID:
21685536
7.

Factors associated with the selection of mutations conferring resistance to protease inhibitors (PIs) in PI-experienced patients displaying treatment failure on darunavir.

Lambert-Niclot S, Flandre P, Canestri A, Peytavin G, Blanc C, Agher R, Soulié C, Wirden M, Katlama C, Calvez V, Marcelin AG.

Antimicrob Agents Chemother. 2008 Feb;52(2):491-6. Epub 2007 Nov 26.

8.

Darunavir: a review of its use in the management of HIV infection in adults.

McKeage K, Perry CM, Keam SJ.

Drugs. 2009;69(4):477-503. doi: 10.2165/00003495-200969040-00007. Review.

PMID:
19323590
9.

Resistance profiles observed in virological failures after 24 weeks of amprenavir/ritonavir containing regimen in protease inhibitor experienced patients.

Marcelin AG, Affolabi D, Lamotte C, Mohand HA, Delaugerre C, Wirden M, Voujon D, Bossi P, Ktorza N, Bricaire F, Costagliola D, Katlama C, Peytavin G, Calvez V.

J Med Virol. 2004 Sep;74(1):16-20.

PMID:
15258963
10.

Darunavir inhibitory quotient predicts the 48-week virological response to darunavir-based salvage therapy in human immunodeficiency virus-infected protease inhibitor-experienced patients.

Moltó J, Santos JR, Pérez-Alvarez N, Cedeño S, Miranda C, Khoo S, Else L, Llibre JM, Valle M, Clotet B.

Antimicrob Agents Chemother. 2008 Nov;52(11):3928-32. doi: 10.1128/AAC.00520-08. Epub 2008 Aug 25.

11.

Human immunodeficiency virus type 1 genotypic and pharmacokinetic determinants of the virological response to lopinavir-ritonavir-containing therapy in protease inhibitor-experienced patients.

Masquelier B, Breilh D, Neau D, Lawson-Ayayi S, Lavignolle V, Ragnaud JM, Dupon M, Morlat P, Dabis F, Fleury H; Groupe d' Epidémiologie Clinique du SIDA en Aquitaine.

Antimicrob Agents Chemother. 2002 Sep;46(9):2926-32.

12.

Resistant minority species are rarely observed in patients on darunavir/ritonavir monotherapy.

Lambert-Niclot S, Flandre P, Valantin MA, Peytavin G, Sayon S, Morand-Joubert L, Delaugerre C, Algarte-Genin M, Katlama C, Calvez V, Marcelin AG.

J Antimicrob Chemother. 2012 Jun;67(6):1470-4. doi: 10.1093/jac/dks052. Epub 2012 Mar 5.

PMID:
22396434
13.

Identification of new genotypic cut-off levels to predict the efficacy of lopinavir/ritonavir and darunavir/ritonavir in the TITAN trial.

Hill A, Marcelin AG, Calvez V.

HIV Med. 2009 Nov;10(10):620-6. doi: 10.1111/j.1468-1293.2009.00734.x. Epub 2009 Jul 6.

14.

Analysis of the virological response with respect to baseline viral phenotype and genotype in protease inhibitor-experienced HIV-1-infected patients receiving lopinavir/ritonavir therapy.

Kempf DJ, Isaacson JD, King MS, Brun SC, Sylte J, Richards B, Bernstein B, Rode R, Sun E.

Antivir Ther. 2002 Sep;7(3):165-74.

PMID:
12487383
15.

Efficacy of once-daily darunavir/ritonavir 800/100 mg in HIV-infected, treatment-experienced patients with no baseline resistance-associated mutations to darunavir.

De Meyer SM, Spinosa-Guzman S, Vangeneugden TJ, de Béthune MP, Miralles GD.

J Acquir Immune Defic Syndr. 2008 Oct 1;49(2):179-82. doi: 10.1097/QAI.0b013e318183a959.

PMID:
18769351
16.

Virological responses to atazanavir-ritonavir-based regimens: resistance-substitutions score and pharmacokinetic parameters (Reyaphar study).

Pellegrin I, Breilh D, Ragnaud JM, Boucher S, Neau D, Fleury H, Schrive MH, Saux MC, Pellegrin JL, Lazaro E, Vray M.

Antivir Ther. 2006;11(4):421-9.

PMID:
16856615
18.

Effect of baseline viral susceptibility on response to darunavir/ritonavir versus control protease inhibitors in treatment-experienced HIV type 1-infected patients: POWER 1 and 2.

Pozniak A, Opravil M, Beatty G, Hill A, de Béthune MP, Lefebvre E.

AIDS Res Hum Retroviruses. 2008 Oct;24(10):1275-80. doi: 10.1089/aid.2007.0275.

PMID:
18844462
19.

Subgroup analysis of virological response rates with once- and twice-daily darunavir/ritonavir in treatment-experienced patients without darunavir resistance-associated mutations in the ODIN trial.

Sension M, Cahn P, Domingo P, Hodder S, Opsomer M, Lathouwers E, Van de Casteele T, Tomaka F.

HIV Med. 2013 Aug;14(7):437-44. doi: 10.1111/hiv.12024. Epub 2013 Mar 10.

20.

Clinical validation of saquinavir/ritonavir genotypic resistance score in protease-inhibitor-experienced patients.

Marcelin AG, Flandre P, de Mendoza C, Roquebert B, Peytavin G, Valer L, Wirden M, Abbas S, Katlama C, Soriano V, Calvez V.

Antivir Ther. 2007;12(2):247-52.

PMID:
17503666

Supplemental Content

Support Center